These genetic disorders result from reduced levels of gonadotropin and sex steroids in the absence of anatomical or functional abnormalities of the hypothalamic–pituitary–gonadal axis.

One of the main treatments for CPP is the use of gonadotropin-releasing hormone analogs (GnRHa), which help to delay the progression of puberty and can positively influence final adult height ...